An Open Label, Balanced, Randomized, Two-Treatment, Two-Sequence, Four-Period, Full Replicate, Crossover, Single Dose, Oral Comparative Bioavailability Study of XS004 (Dasatinib) 100 mg Film-Coated Tablets, Formulation G of Xspray Pharma AB, Sweden, and SPRYCEL® (Dasatinib) 140 mg Film-Coated Tablets of Bristol-Myers Squibb Company, Princeton, NJ 08543 USA in Healthy, Adult Subjects Under Fasting Conditions
Latest Information Update: 10 Sep 2024
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacokinetics
- Sponsors Xspray Pharma
Most Recent Events
- 06 Sep 2024 According to Xspray Pharma media release, data from this study published in the US journal Clinical Pharmacology in Drug Development
- 06 Sep 2024 Results published in the Xspray Pharma Media Release
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition